Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy. 9. Positive results of screening test for human immunodeficiency virus (HIV). 10. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day meth ylprednisolone), excluding inhaled steroids. Short- term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed. NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 1 Confidential and Proprietary 12 11. Known hypersensitivity to any component of the study medication(s). 12. Subjec ts taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications. 13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarith romycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1. 14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1. 15. Participation in an investigational drug study or history of receiving any investigat ional treatment within 30 days prior to initiation of treatment on this study, except for testosterone- lowering therapy in men with prostate cancer. 16. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol. 17. Concurrent participation in any interventional clinical trial. 18. Pregnant and nursing women. NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 1 Confidential and Proprietary 13 Products, Dosage, and Mode of Administration: Investigational Products Dosage Mode of Administration Aldoxorubicin HCl 80 mg/m2 or 30 mg/m2 (induction); 60 mg/m2 (maintenance) IV ALT -803 10 µg/kg SC ETBX -011 1 × 1011 VP/dose SC ETBX -051 1 × 1011 VP/dose SC ETBX -061 1 × 1011 VP/dose SC GI-4000 40 YU/dose SC GI-6207 40 YU/dose SC GI-6301 40 YU/dose SC haNK cells 2 × 109 cells/dose IV Approved Products Dosage Mode of Administration Avelumab 10 mg/kg IV Bevacizumab 5 mg/kg IV Capecitabine 650 mg/m2 PO BID Cisplatin 40 mg/m2 IV Cyclophosphamide 25 mg PO BID 5-FU 1500 mg/m2 85- to 96-hour continuous IV infusion Leucovorin 20 mg/m2 IV bolus Approved Products Dosage Mode of Administration Nab-paclitaxel 125 mg (induction); 100 mg (maintenance) IV Omega -3-acid ethyl esters 2 g PO BID SBRT 8 Gy maximum (exact dose to be determined by the radiation oncologist) External beam radiation Duration of Treatment: • Induction phase: 8 weeks (minimum) to 1 year (maximum). • Maintenance phase: Up to 1 year.